The NLRP3 inflammasome is a potential upstream target for future DR therapeutics as it plays a key part of the innate immune system that orchestrates inflammatory cascades and is dysregulated in chronic inflammatory diseases such as in T2DM [21, 68]. Here, NLRP3 is linked to type 2 diabetes mellitus.